Drug profile · INN
inclisiran sodium
LEQVIO
inclisiran sodium (LEQVIO) is a pcsk9 mrna rnai inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — inclisiran sodium
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 9
- Programs
- 4
- Data quality
- 0.84
Quick answer
inclisiran sodium (LEQVIO) is a pcsk9 mrna rnai inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
PCSK9 mRNA rnai inhibitor
Primary target: PCSK9 mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10851377
Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
granted -
US 10806791
Carbohydrate conjugates as delivery agents for oligonucleotides
granted -
US 10131907
Glycoconjugates of RNA interference agents
granted -
US 10125369
PCSK9 iRNA compositions and methods of use thereof
granted -
US 9370582
Carbohydrate conjugates as delivery agents for oligonucleotides
granted -
US 8828956
Carbohydrate conjugates as delivery agents for oligonucleotides
granted -
US 8809292
Compositions and methods for inhibiting expression of the PCSK9 gene
granted -
US 8222222
Compositions and methods for inhibiting expression of the PCSK9 gene
granted -
US 8106022
Carbohydrate conjugates as delivery agents for oligonucleotides
granted
Frequently asked questions
What is inclisiran sodium?
inclisiran sodium (LEQVIO) is a pcsk9 mrna rnai inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for inclisiran sodium?
LEQVIO is a marketed brand name for inclisiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of inclisiran sodium?
inclisiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.